🍽️ mevastatin,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Cholesterol Reduction: Mevastatin works by inhibiting an enzyme called HMG-CoA reductase, which plays a key role in the production of cholesterol in the liver. By blocking this enzyme, mevastatin reduces the synthesis of cholesterol, leading to lower levels of total cholesterol and low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol.

  2. Prevention of Atherosclerosis: Elevated levels of LDL cholesterol are a major risk factor for the development of atherosclerosis, a condition characterized by the buildup of plaque in the arteries. By lowering LDL cholesterol levels, mevastatin helps reduce the risk of atherosclerosis, which can lead to heart attack, stroke, and other cardiovascular complications.

  3. Improvement of Cardiovascular Health: Lowering LDL cholesterol with mevastatin has been shown to reduce the incidence of cardiovascular events, including heart attack, stroke, and the need for revascularization procedures such as angioplasty or coronary artery bypass surgery. It can also help improve overall cardiovascular health and reduce mortality associated with cardiovascular disease.

  4. Increase in High-Density Lipoprotein (HDL) Cholesterol: In addition to lowering LDL cholesterol, mevastatin may modestly increase levels of high-density lipoprotein (HDL) cholesterol, often referred to as "good" cholesterol. HDL cholesterol helps remove LDL cholesterol from the bloodstream, which further contributes to cardiovascular protection.

  5. Anti-Inflammatory Effects: Statins like mevastatin have been found to have anti-inflammatory properties beyond their cholesterol-lowering effects. Chronic inflammation is associated with the development and progression of atherosclerosis, and statins may help reduce inflammation within the arterial walls, thereby slowing the progression of the disease.

  6. Prevention of Cardiovascular Events: Mevastatin is commonly prescribed for individuals at high risk of cardiovascular events, such as those with coronary artery disease, diabetes, or other risk factors for cardiovascular disease. By reducing cholesterol levels and exerting other beneficial effects on the cardiovascular system, mevastatin can help prevent heart attacks, strokes, and related complications.

  7. Side Effects: While mevastatin is generally well-tolerated, like other statins, it may cause side effects in some individuals. Common side effects may include muscle pain or weakness (myopathy), liver enzyme abnormalities, gastrointestinal symptoms (such as nausea, diarrhea, or constipation), and headache. Rare but serious side effects may include muscle breakdown (rhabdomyolysis) and liver toxicity.

  8. Drug Interactions: Mevastatin may interact with other medications, particularly those metabolized by the same liver enzyme system, increasing the risk of side effects or reducing the effectiveness of either medication. It is important for healthcare providers to review the patient's medication regimen and monitor for potential drug interactions when prescribing mevastatin.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of mevastatin,(prescription) On Probiotics

Rank Probiotic Impact

Bacteria Impacted by mevastatin,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Coprococcus genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Lachnospira genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Roseburia intestinalis species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Agathobacter rectalis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Enterocloster bolteae species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of mevastatin,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 1.2 0.4 2
Age-Related Macular Degeneration and Glaucoma 0.3 0.3 0
Allergic Rhinitis (Hay Fever) 0.3 0.3
Allergies 0.1 1.5 -14
Allergy to milk products 0.5 0.3 0.67
Alopecia (Hair Loss) 1 1
Alzheimer's disease 0.9 2.6 -1.89
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1 0.4 1.5
Ankylosing spondylitis 1.9 0.7 1.71
Anorexia Nervosa 0.3 1.2 -3
Antiphospholipid syndrome (APS) 0.9 0.9
Asthma 0.4 -0.4
Atherosclerosis 0.4 1 -1.5
Atrial fibrillation 1.7 1 0.7
Autism 3.3 3.6 -0.09
Barrett esophagus cancer 0.2 -0.2
Bipolar Disorder 0.7 1.1 -0.57
Brain Trauma 0.4 -0.4
Carcinoma 1 0.7 0.43
Celiac Disease 0.4 1 -1.5
Cerebral Palsy 0.2 0.8 -3
Chronic Fatigue Syndrome 1.8 3.1 -0.72
Chronic Kidney Disease 0.9 1.3 -0.44
Chronic Lyme 0.4 -0.4
Chronic Obstructive Pulmonary Disease (COPD) 0.6 1 -0.67
Chronic Urticaria (Hives) 0.2 0.8 -3
Coagulation / Micro clot triggering bacteria 0.5 0.9 -0.8
Colorectal Cancer 1.6 0.1 15
Constipation 0.4 0.3 0.33
Coronary artery disease 0.6 0.4 0.5
COVID-19 1.2 5 -3.17
Crohn's Disease 1.7 2.6 -0.53
cystic fibrosis 0.4 -0.4
deep vein thrombosis 0.9 -0.9
Depression 2.8 3.2 -0.14
Dermatomyositis 0.2 0.2
Eczema 0.8 -0.8
Endometriosis 1 0.6 0.67
Epilepsy 0.4 0.5 -0.25
Fibromyalgia 0.8 1.6 -1
Functional constipation / chronic idiopathic constipation 1.9 2.2 -0.16
gallstone disease (gsd) 0.7 0.3 1.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.2 0.2 0
Generalized anxiety disorder 0.5 -0.5
Glioblastoma 0.2 -0.2
Gout 0.4 -0.4
Graves' disease 0.3 0.3 0
Halitosis 0 0.2 0
Hashimoto's thyroiditis 1 0 0
Hidradenitis Suppurativa 0.2 0.2
Histamine Issues 0.8 0.5 0.6
hyperglycemia 0.3 -0.3
hypertension (High Blood Pressure 1 1.1 -0.1
Hypothyroidism 0.4 -0.4
Hypoxia 0.3 0.3
IgA nephropathy (IgAN) 1.2 -1.2
Inflammatory Bowel Disease 0.8 5.1 -5.37
Insomnia 0.3 0.6 -1
Intelligence 0.5 0.7 -0.4
Intracranial aneurysms 0.7 0.7
Irritable Bowel Syndrome 0.8 1.1 -0.38
Liver Cirrhosis 1.7 1.4 0.21
Long COVID 2 3.1 -0.55
Low bone mineral density 1 -1
Lung Cancer 0.4 -0.4
Mast Cell Issues / mastitis 0.2 0.8 -3
ME/CFS with IBS 0.4 0.9 -1.25
ME/CFS without IBS 0.3 1 -2.33
Metabolic Syndrome 1.8 2 -0.11
Mood Disorders 3.6 3.2 0.13
multiple chemical sensitivity [MCS] 0.6 0.6
Multiple Sclerosis 1.3 3.8 -1.92
Multiple system atrophy (MSA) 0.4 -0.4
neuropathic pain 0.3 -0.3
Neuropathy (all types) 0.2 0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.9 1.4 -0.56
Obesity 2.3 1.6 0.44
obsessive-compulsive disorder 1.9 1.9 0
Osteoarthritis 0.3 0.4 -0.33
Osteoporosis 0.5 0 0
pancreatic cancer 0.2 0.2
Parkinson's Disease 0.9 2.5 -1.78
Polycystic ovary syndrome 0.8 1.1 -0.38
Postural orthostatic tachycardia syndrome 0.4 -0.4
Premenstrual dysphoric disorder 0.3 -0.3
primary biliary cholangitis 0.1 -0.1
Psoriasis 0.8 2.7 -2.38
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.6 0.9 1.89
Rosacea 1 0.3 2.33
Schizophrenia 1.4 1.1 0.27
scoliosis 0.4 0.9 -1.25
Sjögren syndrome 1.2 0.5 1.4
Sleep Apnea 0.8 0.8 0
Small Intestinal Bacterial Overgrowth (SIBO) 0.2 0.2
Stress / posttraumatic stress disorder 0.7 0.8 -0.14
Systemic Lupus Erythematosus 1.1 1 0.1
Tic Disorder 0.5 0.7 -0.4
Tourette syndrome 0 0
Type 1 Diabetes 1.1 0.9 0.22
Type 2 Diabetes 1.9 2 -0.05
Ulcerative colitis 0.3 1.9 -5.33
Unhealthy Ageing 1.7 1 0.7

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]